| Literature DB >> 34084397 |
Shae-Lynn J Lahey1, Christopher N Rowley1.
Abstract
Drug molecules adopt a range of conformations both in solution and in their protein-bound state. The strain and reduced flexibility of bound drugs can partially counter the intermolecular interactions that drive protein-ligand binding. To make accurate computational predictions of drug binding affinities, computational chemists have attempted to develop efficient empirical models of these interactions, although these methods are not always reliable. Machine learning has allowed the development of highly-accurate neural-network potentials (NNPs), which are capable of predicting the stability of molecular conformations with accuracy comparable to state-of-the-art quantum chemical calculations but at a billionth of the computational cost. Here, we demonstrate that these methods can be used to represent the intramolecular forces of protein-bound drugs within molecular dynamics simulations. These simulations are shown to be capable of predicting the protein-ligand binding pose and conformational component of the absolute Gibbs energy of binding for a set of drug molecules. Notably, the conformational energy for anti-cancer drug erlotinib binding to its target was found to be considerably overestimated by a molecular mechanical model, while the NNP predicts a more moderate value. Although the ANI-1ccX NNP was not trained to describe ionic molecules, reasonable binding poses are predicted for charged ligands, but this method is not suitable for modeling charged ligands in solution. This journal is © The Royal Society of Chemistry.Entities:
Year: 2020 PMID: 34084397 PMCID: PMC8157423 DOI: 10.1039/c9sc06017k
Source DB: PubMed Journal: Chem Sci ISSN: 2041-6520 Impact factor: 9.825
Fig. 1Calculated poses of ligands (red) in protein binding sites. The crystallographic electron density of the ligands are shown in blue. The PDB ID, protein name, and ligand name are included beneath the image.
Conformational Gibbs energy of binding for protein–ligand complexes calculated using the MM(CGenFF) and NNP/MM methods. All energies are in kcal mol−1
| PDB ID | Δ | Δ | Charge |
|---|---|---|---|
|
| 0.4 ± 0.0 | 0.5 ± 0.0 | 0 |
|
| 4.7 ± 0.1 | 5.2 ± 0.1 | 0 |
|
| 1.9 ± 0.1 | 1.0 ± 0.2 | 0 |
|
| 13.0 ± 0.1 | 8.3 ± 0.1 | 0 |
|
| 3.4 ± 0.1 | 2.3 ± 0.1 | 0 |
|
| 8.1 ± 0.1 | 326.9 ± 0.1 | 1 |
|
| 11.1 ± 0.0 | 37.7 ± 0.0 | −2 |
|
| 5.6 ± 0.1 | 15.2 ± 0.2 | 1 |
Fig. 2The potential of mean force for the deviation of the structure of erlotinib from its bound conformation when it is bound to EGFR (top, PDB ID: 4HJO) and when it is in solution (bottom) calculated using the hybrid NNP/MM and pure MM(CGenFF) methods.
Fig. 3(a) The fragment of erlotinib used to calculate the potential energy surface. Truncated groups are shown in grey. (b) Representative solution conformations of erlotinib for the CGenFF MM model (green) and NNP/MM model (red) overlaid with the ligand pose from the 4HJO crystal structure. (c) The relaxed potential energy surfaces for rotation around the erlotinib fragment amine bonds calculated using (i) DLPNO-CCSD/def2-TZVP//MP2/def2-TZVP (ii) NNP(ANI-1ccX) and (iii) the CGenFF MM model. Energies are in kcal mol−1.